Stocklytics Platform
Asset logo for symbol AVTE
Aerovate Therapeutics
AVTE52
$2.72arrow_drop_down0.36%-$0.01
Penny Stock
Asset logo for symbol AVTE
AVTE52

$2.72

arrow_drop_down0.36%
Key Stats
Open$2.74
Prev. Close$2.74
EPS-2.99
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$79.70M
PE Ratio-
LOWHIGH
Day Range2.56
4.12
52 Week Range1.25
32.41
Ratios
Revenue-
EBITDA Margin %-
EPS-2.99
Fundamentals
Gross Profit-
Payout Ratio-
Industry average yield2.89%
Last Dividend pay date-
Dividend per share-
Dividend yield forecast-

Stock Analysis

Technicals

Summarizing what the indicators are suggesting.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Analyst rating

An aggregate view of professional's ratings.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Stock Performance

AVTE-
US Healthcare Sector-
US Market-
warning

AVTE / Market

AVTE matched the US Market which returned -0.36% over the last twenty four hours.
warning

AVTE / Healthcare Sector

AVTE lose to the US Healthcare sector which returned 2.12% over the last twenty four hours.

Aerovate Therapeutics (AVTE) Statistics

Aerovate Therapeutics, Inc. (AVTE) is a company that specializes in the field of therapeutics. As of now, there are limited statistics available for AVTE stock. However, it is important to note that stock statistics can provide valuable insights into the performance of a company in the stock market. These statistics may include data such as the stock price, trading volume, market capitalization, and dividend yield. By analyzing these metrics, investors can get a better understanding of how the stock is performing compared to its peers and the overall market.
In terms of valuation metrics, AVTE has not provided detailed information. Valuation metrics are used to assess the intrinsic value of a company's stock. These metrics may include the price-to-earnings ratio, price-to-sales ratio, price-to-book ratio, and dividend yield. By analyzing these metrics, investors can determine whether a stock is overvalued or undervalued relative to its financial performance.
add Aerovate Therapeutics to watchlist

Keep an eye on Aerovate Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

How has Aerovate Therapeutics (AVTE) stock's performance compared to its sector and the market over the past year?

Over the past year, Aerovate Therapeutics (AVTE) has experienced a price change of . Compared to the Healthcare sector, which saw a change of 17.28%, Aerovate Therapeutics has underperformed compared to its sector, indicating its relative standing within the Healthcare sector. Against the broader market's change of 24.68%, it has fallen short of the market average. This comparison highlights Aerovate Therapeutics's performance relative to both its sector and the overall market over the last year.
help

What is the PE ratio of Aerovate Therapeutics (AVTE) stock?

The PE ratio for Aerovate Therapeutics (AVTE) is currently not available. This could be due to a variety of factors such as the company not having positive earnings at the moment or recent updates not being reflected.
help

What is the EPS of Aerovate Therapeutics (AVTE) stock?

The Earnings Per Share (EPS) for Aerovate Therapeutics (AVTE), calculated on a diluted basis, is -$2.99. EPS is a key indicator of a company's profitability, showing the portion of a company's profit allocated to each outstanding share of common stock.
help

What is the operating margin of Aerovate Therapeutics (AVTE) stock?

The operating margin for Aerovate Therapeutics (AVTE) is 0%. This metric represents the percentage of revenue that remains after paying for variable production costs, indicating the efficiency and profitability of the company's core business operations.
help

What is the EBITDA of Aerovate Therapeutics (AVTE) stock?

The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of Aerovate Therapeutics (AVTE) is -$74.31M. EBITDA is a widely used earnings metric to assess a company's operational efficiency and profitability before the impact of non-operating decisions such as financing, accounting, and tax environments.
help

How much debt does Aerovate Therapeutics (AVTE) have?

Aerovate Therapeutics (AVTE) has a total debt of $417K. The net debt, which accounts for cash and cash equivalents against the total debt, is -$30.58M.

Take Your Investments to a Whole New Level